Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

Summary by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2026 earnings guidance. The company provided EPS guidance of 2.800-3.100 for the period, compared to the consensus estimate of 3.320. The company also issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus estimate of $3.9 billion.

1 Articles

MarketBeatMarketBeat
Center

BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2026 earnings guidance. The company provided EPS guidance of 2.800-3.100 for the period, compared to the consensus estimate of 3.320. The company also issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus estimate of $3.9 billion.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Tuesday, November 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Rafael icon

San Rafael

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal